Comparing Pain, Safety and Effectiveness of Restylane Skinboosters Vital Lido and Vital Without Lido in Dorsal Hand

NCT ID: NCT06372782

Last Updated: 2025-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-24
• Study Completion Date: 2024-07-16

Brief Summary

This is a randomized, multi-center, split-hand, subject-blinded study comparing pain, safety and effectiveness of Restylane Skinboosters Vital Lidocaine and Restylane Vital without lidocaine for improving appearance of the dorsal hands in Chinese subjects.

Conditions

Skin Aging of Dorsal Hands

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

Restylane Skinboosters Vital Lidocaine

Participant's one hand treated by Restylane Skinboosters Vital Lidocaine

Group Type: EXPERIMENTAL

Restylane Skinboosters Vital Lidocaine

Intervention Type: DEVICE

Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.

Restylane Vital

Participant's another hand treated by Restylane Vital

Group Type: ACTIVE_COMPARATOR

Restylane Vital

Intervention Type: DEVICE

Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned

Interventions

Restylane Skinboosters Vital Lidocaine

Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.

Intervention Type: DEVICE

Restylane Vital

Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Signed and dated informed consent to participate in the study

2. Chinese origin

3. Age at least 18 years

4. The subject is willing and able to comply with the requirements of the study and agrees to adhere to the visit schedule and to be compliant to the study instructions

5. Subjects eligible for treatment to improve appearance of the dorsal hand by increasing tissue volume

6. Same grade of tissue degeneration and need for treatment in both hands

Exclusion Criteria

1. Any previous non-permanent or permanent implant/filler in the hands, including autologous fat

2. Any mesotherapy or resurfacing procedure (laser, chemical peels or other ablative or non-ablative treatment) in the hands within 6 months prior to baseline

3. Any previous hand surgery including sclerotherapy

4. Any fibrosis or scarring or deformities on the hands

5. Advanced photoaged/ photodamaged skin (e.g. advanced skin elastosis, multiple lentigo solaris lesions) or skin condition with very crinkled or fragile skin on the dorsal hands

6. Subjects with active skin disease, inflammation or related conditions in the hand

7. Subjects with a history of precancerous (e.g. actinic keratosis) or cancerous lesions in the hands

8. Subjects with a history of Raynaud´s disease or phenomenon, or history of other disease that may affect peripheral circulation

9. History of neurological disease that may affect peripheral neurological function

10. Subjects with a history of autoimmune disease or joint disease or connective tissue disease (e.g. rheumatoid arthritis, lupus, scleroderma etc)

11. Subjects with known hypersensitivity to any ingredient of the study product or anesthesia used in the study or with a history of any significant Adverse Events caused by dermal fillers

12. Use of topical retinoids on the dorsal hands within 6 weeks prior to baseline or use of systemic retinoids within 6 months prior to baseline

13. History of chronic lymph edema or breast cancer /mastectomy with potential to cause edema

14. Concomitant thrombolytic or anticoagulant therapy and therapy with inhibitors of platelet aggregation, (e.g. non-steriod anti-inflammatory drugs, acetylsalicylic acid, Omega 3 and Vitamin E) within 2 weeks prior to treatment, or a history of bleeding disorders. Cyclooxygenase-2 (COX-2) inhibitors are allowed

15. Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (dorsal hands) corticosteroids (inhaled corticoids are allowed) within three months before study treatment

16. History of untreated epilepsy or other significant medical conditions

17. Women who are pregnant or breast feeding, or Woman of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

18. Subjects participating in another interventional clinical study within 30 days of baseline

19. Subjects with unattainable expectation with regard to the aesthetic results of the treatment

20. Subjects who are involved in conducting the study (e.g. colleagues within the same department) or close relatives to any of the study staffs (e.g. parents, children, siblings or spouse ) as well as subjects who are employed by the Sponsor company, or close relatives of employees at the Sponsor company

21. Subjects with any other condition which in the opinion of the Investigator, might compromise the subject's ability to tolerate the injection procedure or comply with requirements of the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Galderma R&D

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Galderma R&D

Role: STUDY_DIRECTOR

Galderma R&D

Locations

Galderma Research Site 01

Shanghai, Shanghai Municipality, China

Galderma Research Site 02

Hangzhou, Zhejiang, China

Galderma Research Site 03

Hangzhou, Zhejiang, China

Countries

China

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

43CH2305

Identifier Type: -

Identifier Source: org_study_id